Printer Friendly

Consort Medical announces proposed acquisition of Aesica Pharmaceuticals.

M2 PHARMA-October 1, 2014-Consort Medical announces proposed acquisition of Aesica Pharmaceuticals

(C)2014 M2 COMMUNICATIONS

Consort Medical plc, a UK-based healthcare company, announced yesterday that it has agreed terms to acquire the entire share capital of Aesica Pharmaceuticals Limited, a UK-based pharmaceutical company.

The deal is valued at GBP230 million, and the closing of the transaction, which is expected to occur in November, is conditional on the approval of Consort Medical's shareholders and clearance by the German competition authorities.

Consort Medical plc develops and manufactures disposable medical devices for drug delivery, including inhaled, nasal and injectables products through its core operating division, Bespak.

Aesica provides contract development and manufacturing services for Finished Dose and Active Pharmaceutical Ingredients ("API") to the global pharmaceutical industry.

Jon Glenn, Consort Medical plc's CEO said: 'We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain. As one of Europe's leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak's existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group.'

(EUR1 = GBP0.79)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 1, 2014
Words:209
Previous Article:Pfizer to coollaborate with Kyowa Hakko Kirin On Immuno-Oncology Combination Study.
Next Article:Johnson & Johnson to purchase Alios BioPharma to strengthen existing viral diseases pipeline.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters